Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Semma will become a separate operating subsidiary of Vertex. Semma is working to advance Melton’s methodology for creating billions of functional, insulin-producing beta cells.
Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.
TLC announced that the management team is scheduled to present at the two upcoming investor conferences
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014
Investment in life sciences innovation at all-time high, driving demand for new real estate concepts
U.S. biopharmaceutical research and development spending reached a record $179 billion in 2018 and is expected to grow by $34 billion by 2024, an indication that companies are investing now to improve their future pipelines, according to JLL’s eighth annual Life Sciences Outlook.
“This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage Fintepla programs,” stated Stephen J. Farr, president and chief executive officer of Zogenix.
Resverlogix Corp. announced that its Annual and Special Meeting of Shareholders is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall, 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at approximately 1:00 pm.